TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2663160

Group type: EXPERIMENTAL
Intervention: Cefonicid (1 gm, intravenously or intramuscularly, daily for 3 to 11 days, mean 7 days)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (1 gm, intravenously or intramuscularly, daily for 3 to 11 days, mean 7 days)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Ceftriaxone (Control)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Cefonicid (Control)
Number of subjects: 118
Study: 31371167

Group type: EXPERIMENTAL
Intervention: Surgical intervention for distal femoral fractures (specifics not provided)
Number of subjects: 11
Study: 28865586

Group type: EXPERIMENTAL
Intervention: VAC treatment by means of Y-connector
Number of subjects: 21

Group type: COMPARATOR
Intervention: bridge-VAC treatment
Number of subjects: 21
Study: 26148618

Group type: COMPARATOR
Intervention: Healthy people (control group)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Colorectal cancer patients
Number of subjects: 235
Study: 23113965

Group type: COMPARATOR
Intervention: Olmesartan (20 mg/d) plus Rosuvastatin (10 mg/d)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Manidipine (20 mg/d) plus Rosuvastatin (10 mg/d)
Number of subjects: 40
Study: 21586508

Group type: EXPERIMENTAL
Intervention: budesonide/formoterol 160/4.5 µg, 2 × 2 treatment
Number of subjects: 8424

Group type: COMPARATOR
Intervention: budesonide/formoterol 160/4.5 µg, 1 × 2 treatment
Number of subjects: 8424
Study: 17683501

Group type: EXPERIMENTAL
Intervention: Rectal diclofenac (100 mg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 16433868

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (3 mg min(‐1) i.v. infusion over 100 min)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Pentoxifylline with ciprofloxacin
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Pentoxifylline with rifampicin
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Pentoxifylline after rifampicin pretreatment
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Pentoxifylline and its metabolites
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (i.v. infusion over 100 min)
Number of subjects: 8
Study: 11996479

Group type: EXPERIMENTAL
Intervention: Ifosfamide/carboplatin/etoposide (ICE) chemotherapy consisting of ifosfamide 1800 mg/m2/day (on day 0-4), carboplatin 400 mg/m2/day (on day 0-1), and etoposide 100 mg/m2/day (on day 0-4)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Ifosfamide/carboplatin/etoposide (ICE) chemotherapy
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Ifosfamide/carboplatin/etoposide (ICE) chemotherapy followed by post-ICE therapy
Number of subjects: 11
Study: 9952016

Group type: EXPERIMENTAL
Intervention: Nephro‐Vite Rx (once daily for 3 weeks)
Number of subjects: 11
Study: 7750007

Group type: EXPERIMENTAL
Intervention: Active extract (Alpare Parietaria) with a targeted maintenance dose of 12,500 BUs for 2 years
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Active extract (Alpare Parietaria)
Number of subjects: 36
Study: 2245814

Group type: EXPERIMENTAL
Intervention: Sucralphate
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control
Number of subjects: 51
Study: 6251487

Group type: EXPERIMENTAL
Intervention: Stannous fluoride-calcium pyrophosphate (SnF2-CPP) dentifrice
Number of subjects: 1337

Group type: COMPARATOR
Intervention: Placebo control dentifrice
Number of subjects: 1337
Study: 6141896

Group type: EXPERIMENTAL
Intervention: loprazolam 1 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: loprazolam 2 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study: 30664462

Group type: EXPERIMENTAL
Intervention: PoP website (The Power of Placebos)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Control website (existing information leaflets from UK trials)
Number of subjects: 350
Study: 30672230

Group type: EXPERIMENTAL
Intervention: Muscle tension staged acupuncture
Number of subjects: 62

Group type: COMPARATOR
Intervention: Conventional acupuncture
Number of subjects: 62
Study: 26813298

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTX) 150 mL, 2 U/mL
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo (150 mL 0.9% NaCl)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTX)
Number of subjects: 46
Study: 24644183

Group type: EXPERIMENTAL
Intervention: Methoxyflurane (MEOF)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 22988932

Group type: EXPERIMENTAL
Intervention: SKP-1052 (2.5 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: SKP-1052 (5 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: IRT (5 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 19260039

Group type: EXPERIMENTAL
Intervention: Cognizin citicoline 2,000 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognizin citicoline 500 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 17414932

Group type: EXPERIMENTAL
Intervention: ATV/r at a dose of 300/100 mg once daily (Period I)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: ATV at a dose of 300 mg once daily plus LPV/r at a dose of 400/100 mg twice daily (Period II)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: ATV/r at a dose of 300/100 mg once daily plus LPV/r at a dose of 400/100 mg twice daily (Period III)
Number of subjects: 15

Group type: COMPARATOR
Intervention: LPV/r at a dose of 400/100 mg twice daily (historical control)
Number of subjects: 15
Study: 16095446

Group type: EXPERIMENTAL
Intervention: Cuff Pressure Release Valve (CPRV) set to 25 cmH2O
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (without CPRV)
Number of subjects: 50
Study: 11897259

Group type: EXPERIMENTAL
Intervention: Functional energy drink (FED) - 250 ml containing sucrose, glucose, 80 mg caffeine, taurine, glucuronolactone, and vitamins
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control drink - 250 ml with the same volume and taste but without caffeine, taurine, and glucuronolactone
Number of subjects: 12
Study: 10353472

Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) measurement in group A at onset of infection (d1)
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: C-Reactive Protein (CRP) measurement in group A at onset of infection (d1)
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) measurement in group B at onset of infection (d1)
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: C-Reactive Protein (CRP) measurement in group B at onset of infection (d1)
Number of subjects: 563

Group type: COMPARATOR
Intervention: Procalcitonin (PCT) measurement in group C (control) at d1
Number of subjects: 563

Group type: COMPARATOR
Intervention: C-Reactive Protein (CRP) measurement in group C (control) at d1
Number of subjects: 563

Group type: COMPARATOR
Intervention: Procalcitonin (PCT) measurement in group C (control) at d3
Number of subjects: 563

Group type: COMPARATOR
Intervention: C-Reactive Protein (CRP) measurement in group C (control) at d3
Number of subjects: 563

Group type: COMPARATOR
Intervention: Procalcitonin (PCT) measurement in group C (control) at d5
Number of subjects: 563

Group type: COMPARATOR
Intervention: C-Reactive Protein (CRP) measurement in group C (control) at d5
Number of subjects: 563
Study: 8669598

Group type: EXPERIMENTAL
Intervention: Enoximone
Number of subjects: 16

Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Dobutamine
Number of subjects: 16
Study: 2213262

Group type: EXPERIMENTAL
Intervention: Fiberoptic phototherapy
Number of subjects: 46

Group type: COMPARATOR
Intervention: Traditional phototherapy
Number of subjects: 46
Study: 6110383

Group type: EXPERIMENTAL
Intervention: KWD 2131 (0.3 mg or 0.6 mg subcutaneous injection)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Terbutaline (not specified in dosage)
Number of subjects: 12
Study: 31034809

Group type: EXPERIMENTAL
Intervention: e-learning system for endoscopic diagnosis of EGC
Number of subjects: 365
Study: 28580602

Group type: EXPERIMENTAL
Intervention: Recorded maternal voices
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no recorded maternal voices)
Number of subjects: 40
Study: 27559351

Group type: EXPERIMENTAL
Intervention: GC Gold Label
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: GC Fuji Plus
Number of subjects: 186
Study: 23683764

Group type: EXPERIMENTAL
Intervention: Supine position (n=92)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Leg-elevation position (n=93)
Number of subjects: 185
Study: 21861032

Group type: EXPERIMENTAL
Intervention: HP (2 applications of 10 min each)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: HP + LED laser (2 applications of 10 min each/45 s of light activation)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: HP
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: HP + LED laser
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (unbleached)
Number of subjects: 100
Study: 20530938

Group type: EXPERIMENTAL
Intervention: 75‐gram oral glucose tolerance test (oGTT)
Number of subjects: 25000

Group type: EXPERIMENTAL
Intervention: HAPO data
Number of subjects: 25000
Study: 17192503

Group type: EXPERIMENTAL
Intervention: 5 mg d-methylphenidate (d-MPH)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 10 mg d-methylphenidate (d-MPH)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 20 mg d-methylphenidate (d-MPH)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 30 mg d-methylphenidate (d-MPH)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 40 mg d-methylphenidate (d-MPH)
Number of subjects: 25
Study: 15222108

Group type: EXPERIMENTAL
Intervention: Weekly taxol (TXL) therapy at 60 mg/m2 once a week for 3 weeks with or without a rest week.
Number of subjects: 36
Study: 12392584

Group type: COMPARATOR
Intervention: 150 mg oseltamivir alone (Treatment A)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 150 mg oseltamivir with 20 ml Maalox suspension (Treatment B)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 150 mg oseltamivir with four Titralac tablets (Treatment C)
Number of subjects: 12
Study: 11122796

Group type: EXPERIMENTAL
Intervention: Concurrent cisplatin chemotherapy and radiation therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radiation therapy alone
Number of subjects: 0
Study: 7546755

Group type: EXPERIMENTAL
Intervention: Propofol-fentanyl
Number of subjects: 102

Group type: COMPARATOR
Intervention: Isoflurane-fentanyl
Number of subjects: 102

Group type: COMPARATOR
Intervention: Isoflurane/droperidol
Number of subjects: 102
Study: 2125402

Group type: COMPARATOR
Intervention: Glucose alone (7.2 kcal/day, D5W + C)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Glucose and a conventional amino acid solution (7.2 kcal/day and 0.15 gN/day, CAA + C)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Glucose and branched chain amino acid enriched solution (7.2 kcal/day and 0.14 gN/day, BCAA + C)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Glucose alone (7.2 kcal/day, D5W)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Glucose and a conventional amino acid solution (7.2 kcal/day and 0.14 gN/day, CAA)
Number of subjects: 68
Study: 6770952

Group type: EXPERIMENTAL
Intervention: Elemental diet
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Whole-protein diet
Number of subjects: 40
Study: 30285850

Group type: EXPERIMENTAL
Intervention: Systematic approach to recruitment of care homes
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Targeted approach to recruitment of care homes
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Overall recruitment approach
Number of subjects: 245
Study: 26650380

Group type: EXPERIMENTAL
Intervention: Central fat mass
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peripheral fat mass
Number of subjects: 0
Study: 25440099

Group type: EXPERIMENTAL
Intervention: Modified Blalock-Taussig shunt (MBTS)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Right ventricle to pulmonary artery shunt (RVPAS)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Both shunt types
Number of subjects: 240
Study: 22686571

Group type: EXPERIMENTAL
Intervention: Laryngoscopy-guided insertion technique
Number of subjects: 108

Group type: COMPARATOR
Intervention: Standard technique (digital manipulation)
Number of subjects: 108
Study: 20052502

Group type: EXPERIMENTAL
Intervention: 8 mg dexamethasone
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 55
Study: 18198398

Group type: EXPERIMENTAL
Intervention: Iron fortified ready-to-eat cereal (30 g providing 7.1 mg iron/day) plus pumpkin seed kernels (30 g providing 4.0 mg iron/day) for four weeks
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Iron fortified ready-to-eat cereal and pumpkin seed kernels
Number of subjects: 8
Study: 15177859

Group type: EXPERIMENTAL
Intervention: Lateral position
Number of subjects: 107

Group type: COMPARATOR
Intervention: Supported sitting position
Number of subjects: 107
Study: 12474072

Group type: EXPERIMENTAL
Intervention: Folic acid-fortified wheat breakfast rolls (200 microg/roll) - Group L
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Folic acid-fortified wheat breakfast rolls (400 microg/roll) - Group H
Number of subjects: 29
Study: 9491868

Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol
Number of subjects: 223

Group type: COMPARATOR
Intervention: Dinoprostone vaginal insert
Number of subjects: 223
Study: 7848951

Group type: EXPERIMENTAL
Intervention: Intravenous tenoxicam (20 mg, 2 mL)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Saline solution (2 mL)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups (tenoxicam and saline)
Number of subjects: 80
Study: 3184393

Group type: EXPERIMENTAL
Intervention: Albuterol (salbutamol) inhalation
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 10
Study: 29442239

Group type: COMPARATOR
Intervention: MA 320 mg/day plus placebo
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: MA 320 mg/day plus celecoxib 200 mg/day
Number of subjects: 90
Study: 28295847

Group type: EXPERIMENTAL
Intervention: Case management intervention (monthly home visits by nurses and physiotherapists for 1 year)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 153
Study: 25608502

Group type: EXPERIMENTAL
Intervention: Preconditioning
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Perfusion
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control
Number of subjects: 90
Study: 23229890

Group type: EXPERIMENTAL
Intervention: +mobile group
Number of subjects: 70

Group type: COMPARATOR
Intervention: standard group
Number of subjects: 70
Study: 21914503

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0
Study: 18684777

Group type: EXPERIMENTAL
Intervention: Individual lifestyle counselling (autonomy supportive and self-efficacy enhancing)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Group based rehabilitation
Number of subjects: 176
Study: 16609019

Group type: EXPERIMENTAL
Intervention: High HOXB13/IL‐17BR expression ratio in node-negative cohort (n = 130)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: HOXB13/IL‐17BR ratio in node-positive cohort (n = 86)
Number of subjects: 256
Study: 14596546

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 10889381

Group type: EXPERIMENTAL
Intervention: Adjuvant brachytherapy (BRT)
Number of subjects: 164

Group type: COMPARATOR
Intervention: No adjuvant brachytherapy (no-BRT)
Number of subjects: 164
Study: 8808722

Group type: EXPERIMENTAL
Intervention: Chemotherapy (CP protocol)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Post-surgery treatment (1 and 3 months) during chemotherapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no malignant ovarian tumor)
Number of subjects: 30
Study: 8382537

Group type: EXPERIMENTAL
Intervention: Interferon (IFN) treatment
Number of subjects: 30
Study: 3523589

Group type: EXPERIMENTAL
Intervention: Measured angle beta
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Global impression of the operator
Number of subjects: 167
Study: 29753474

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 100 μg of 25(OH)D3
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 5 μg of LPS
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Combination of 100 μg of 25(OH)D3 and 5 μg of LPS
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: LPS treatment
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 25(OH)D3 treatment
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Interaction of LPS and 25(OH)D3
Number of subjects: 5
Study: 26836244

Group type: EXPERIMENTAL
Intervention: Oral hormone therapy (17β-estradiol combined with norethisterone acetate 2 mg + 1 mg/d) for 24 weeks
Number of subjects: 70

Group type: COMPARATOR
Intervention: Transdermal hormone therapy (17β-estradiol combined with norethisterone acetate 0.05 mg + 5 mg/d) for 24 weeks
Number of subjects: 70

Group type: COMPARATOR
Intervention: Postmenopausal women compared to premenopausal women
Number of subjects: 70
Study: 26122893

Group type: EXPERIMENTAL
Intervention: Spatial orienting to a body site
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Familiar body postures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unusual body postures
Number of subjects: 0
Study: 23537895

Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 35

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 35
Study: 21486162

Group type: EXPERIMENTAL
Intervention: Soy food (SF) - 2 to 3 servings per day providing ∼19 g protein and ∼36 mg isoflavones for 10 weeks
Number of subjects: 63

Group type: COMPARATOR
Intervention: Animal food (AF) - control group
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Soy food (SF)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Animal food (AF)
Number of subjects: 63
Study: 18021495

Group type: EXPERIMENTAL
Intervention: 303 Algorithm (insulin detemir)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-of-care (physician-driven adjustments)
Number of subjects: 0
Study: 18458383

Group type: EXPERIMENTAL
Intervention: rbFGF/ACS (n = 30)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo (petrolatum sterile gauze, n = 28)
Number of subjects: 58
Study: 15037821

Group type: EXPERIMENTAL
Intervention: rosuvastatin 1, 2.5, 5, 10, 20, or 40 mg once daily for 6 weeks
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: rosuvastatin
Number of subjects: 112

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 112
Study: 10846808

Group type: EXPERIMENTAL
Intervention: Semistructured interview exploring social phobic imagery
Number of subjects: 22
Study: 9169246

Group type: EXPERIMENTAL
Intervention: Trazodone (50-250 mg/day)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Haloperidol (1-5 mg/day)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 28

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 28
Study: 8230008

Group type: EXPERIMENTAL
Intervention: Aspirin (average 4.5 g daily)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Other NSAIDs (stable doses)
Number of subjects: 34
Study: 3468491

Group type: EXPERIMENTAL
Intervention: Prophylactic indomethacin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study: 31930891

Group type: EXPERIMENTAL
Intervention: Mild moxibustion combined with salt-separated moxibustion; 15 min per treatment, once a day for 7 days
Number of subjects: 48

Group type: COMPARATOR
Intervention: Intravenous infusion of tropisetron hydrochloride (5 mg), once a day for three days
Number of subjects: 48
Study: 29934198

Group type: EXPERIMENTAL
Intervention: Rasagiline (1 mg/day)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study: 27411352

Group type: EXPERIMENTAL
Intervention: C1M
Number of subjects: 5855

Group type: EXPERIMENTAL
Intervention: VICM
Number of subjects: 5855

Group type: EXPERIMENTAL
Intervention: C4M
Number of subjects: 5855
Study: 23884638

Group type: EXPERIMENTAL
Intervention: Solution-Focused Therapy (SFT)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 98
Study: 22577908

Group type: EXPERIMENTAL
Intervention: Continuous infusion of potassium chloride
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intermittent infusions of potassium chloride
Number of subjects: 100
Study: 20102859

Group type: EXPERIMENTAL
Intervention: PREMIER lifestyle intervention
Number of subjects: 809

Group type: COMPARATOR
Intervention: Control group (traditional lifestyle modifications)
Number of subjects: 809
Study: 18635470

Group type: EXPERIMENTAL
Intervention: Listening to music
Number of subjects: 40

Group type: COMPARATOR
Intervention: No music (Control)
Number of subjects: 40
Study: 15845554

Group type: EXPERIMENTAL
Intervention: High demands, low control, and low support (combined)
Number of subjects: 5562

Group type: EXPERIMENTAL
Intervention: Psychological demands, control, and social support (individual effects)
Number of subjects: 5562

Group type: EXPERIMENTAL
Intervention: Support (DCSQ index)
Number of subjects: 5562

Group type: EXPERIMENTAL
Intervention: Assessment of psychosocial work environment
Number of subjects: 5562
Study: 12455858

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTX‐A) and physiotherapy
Number of subjects: 49

Group type: COMPARATOR
Intervention: Physiotherapy alone
Number of subjects: 49
Study: 10472359

Group type: EXPERIMENTAL
Intervention: High dose sequential chemotherapy (HDS) consisting of cyclophosphamide (7 gr/m2), methotrexate (8 gr/m2), vincristin (2 mg), 2 courses of carboplatin (360 mg/m2), Thiotepa (600 mg/m2), L-PAM (160 mg/m2) with stem cell support
Number of subjects: 14
Study: 8738689

Group type: EXPERIMENTAL
Intervention: Rectal morphine hydrogel 0.2 mg/kg
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Rectal morphine solution 0.2 mg/kg
Number of subjects: 26

Group type: COMPARATOR
Intervention: Intravenous morphine 0.2 mg/kg
Number of subjects: 26
Study: 1400703

Group type: EXPERIMENTAL
Intervention: Methylphenidate (0.3 mg/kg)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Methylphenidate (1.0 mg/kg)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26